Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir tablets on COVID-19 patients

Glenmark Pharmaceuticals on Thursday said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2zDXRFD
via IFTTT